NEW YORK, NY -- (Marketwired) -- 06/06/13 -- Nuvilex, Inc. (OTCQB: NVLX) has a technology in its cell encapsulation process that will very likely play some role in the future of oncology. How large that role will be is contingent upon the technology continuing to return solid results when it's put to the test. One such area where the technology has had a chance to prove its worth is in a preclinical study that was reported in the highly respected scientific publication, International Journal of Cancer.
In that study Nuvilex's cell encapsulation was used together with the well-known anticancer drug ifosfamide and radiation for the treatment of pancreatic tumors in rats. The type of cells encapsulated for the study were the same as those used in the company's two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer. These cells are used because of the highly elevated activity of CYP2B1, the ifosfamide-activating enzyme.
Before the FDA's approval of Eli Lilly's blockbuster drug Gemzar (gemcitabine) in the late 1990s, many patients with advanced, localized inoperable pancreatic cancer were treated with the combination of 5-fluorouracil (5-FU) and radiation. When we talk about "localized" cancers, we mean the cancer has not metastasized or spread to distant organs such as the liver.
After Gemzar was approved, it replaced 5-fluorouracil, and together with radiation became the "treatment of choice" in the US for many patients with inoperable, localized, advanced pancreatic cancer.
This study using Nuvilex's technology was to discover if the cell encapsulation/ifosfamide treatment could work on the preclinical level -- one day potentially being effective in combination with radiation as a multimodality treatment of patients with inoperable, localized, advanced pancreatic cancer.
Continue reading to learn how Nuvilex can replace Gemzar at www.stockmarketmediagroup.com/features.
About Stock Market Media Group
Stock Market Media Group, formerly Stock House Group, is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the media with its Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research on its website for Investors to become better informed on small cap stocks. For more information: www.stockmarketmediagroup.com